Upon initial diagnosis of retinoblastoma, rapid identification of whether it is a germline RB1 mutation, sporadic RB1 mutation or a RB1+/+ MYCNA is necessary for correct treatment, as well as risk assessment for patents and their families [12]. Here, RB1 is linked to retinoblastoma.